Procept BioRobotics [PRCT] vs Penumbra [PEN] Detailed Stock Comparison
Procept BioRobotics
NASDAQ
Loading...
Penumbra
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Procept BioRobotics wins in 4 metrics, Penumbra wins in 14 metrics, with 0 ties. Penumbra appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Procept BioRobotics | Penumbra | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -27.50 | 63.76 | Procept BioRobotics |
| Price-to-Book Ratio | 6.84 | 7.21 | Procept BioRobotics |
| Debt-to-Equity Ratio | 21.02 | 17.04 | Penumbra |
| PEG Ratio | -36.18 | 63.60 | Procept BioRobotics |
| EV/EBITDA | -26.72 | 43.54 | Procept BioRobotics |
| Profit Margin (TTM) | -36.20% | 11.54% | Penumbra |
| Operating Margin (TTM) | -39.67% | 21.87% | Penumbra |
| EBITDA Margin (TTM) | N/A | 21.87% | N/A |
| Return on Equity | -27.62% | 12.03% | Penumbra |
| Return on Assets (TTM) | -13.36% | 7.51% | Penumbra |
| Free Cash Flow (TTM) | $-103.62M | $147.30M | Penumbra |
| Dividend Yield | 0.64% | N/A | N/A |
| 1-Year Return | -25.26% | 41.15% | Penumbra |
| Price-to-Sales Ratio (TTM) | 10.69 | 7.32 | Penumbra |
| Enterprise Value | $2.43B | $9.13B | Penumbra |
| EV/Revenue Ratio | 9.75 | 7.13 | Penumbra |
| Gross Profit Margin (TTM) | 63.85% | 65.99% | Penumbra |
| Revenue per Share (TTM) | $5 | $33 | Penumbra |
| Earnings per Share (Diluted) | $-1.69 | $3.77 | Penumbra |
| Beta (Stock Volatility) | 1.04 | 0.40 | Penumbra |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Procept BioRobotics vs Penumbra Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Procept BioRobotics | -3.07% | -18.39% | -30.51% | -25.46% | -43.09% | -52.39% |
| Penumbra | -0.09% | -4.57% | -3.07% | -16.77% | -7.65% | 0.31% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Procept BioRobotics | -25.26% | 4.46% | 14.23% | 14.23% | 14.23% | 14.23% |
| Penumbra | 41.15% | 39.51% | 2.73% | 481.09% | 481.09% | 481.09% |
Performance & Financial Health Analysis: Procept BioRobotics vs Penumbra
| Metric | PRCT | PEN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.66B | $9.37B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,476,630 | 628,300 |
| 90 Day Avg. Volume | 1,040,502 | 480,977 |
| Last Close | $38.38 | $240.53 |
| 52 Week Range | $37.12 - $103.81 | $164.42 - $310.00 |
| % from 52W High | -63.03% | -22.41% |
| All-Time High | $103.81 (Nov 11, 2024) | $348.67 (Jun 26, 2023) |
| % from All-Time High | -63.03% | -31.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.55% | 0.13% |
| Quarterly Earnings Growth | 0.55% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.36% | 0.12% |
| Operating Margin (TTM) | -0.40% | 0.22% |
| Return on Equity (TTM) | -0.28% | 0.12% |
| Debt to Equity (MRQ) | 21.02 | 17.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.04 | $33.32 |
| Cash per Share (MRQ) | $5.72 | $10.93 |
| Operating Cash Flow (TTM) | $-83,907,000 | $36.77M |
| Levered Free Cash Flow (TTM) | $-58,771,876 | $224.96M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.64% | N/A |
| Last 12-Month Dividend | $0.38 | N/A |
Valuation & Enterprise Metrics Analysis: Procept BioRobotics vs Penumbra
| Metric | PRCT | PEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -27.50 | 63.76 |
| Forward P/E | -36.18 | 63.60 |
| PEG Ratio | -36.18 | 63.60 |
| Price to Sales (TTM) | 10.69 | 7.32 |
| Price to Book (MRQ) | 6.84 | 7.21 |
| Market Capitalization | ||
| Market Capitalization | $2.66B | $9.37B |
| Enterprise Value | $2.43B | $9.13B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.75 | 7.13 |
| Enterprise to EBITDA | -26.72 | 43.54 |
| Risk & Other Metrics | ||
| Beta | 1.04 | 0.40 |
| Book Value per Share (MRQ) | $7.04 | $33.32 |
Financial Statements Comparison: Procept BioRobotics vs Penumbra
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PRCT | PEN |
|---|---|---|
| Revenue/Sales | $69.16M | $324.14M |
| Cost of Goods Sold | $25.00M | $108.26M |
| Gross Profit | $44.16M | $215.88M |
| Research & Development | $16.40M | $22.08M |
| Operating Income (EBIT) | $-27.44M | $40.35M |
| EBITDA | $-22.39M | $49.20M |
| Pre-Tax Income | $-24.74M | $43.86M |
| Income Tax | N/A | $4.64M |
| Net Income (Profit) | $-24.74M | $39.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PRCT | PEN |
|---|---|---|
| Cash & Equivalents | $316.21M | $376.05M |
| Total Current Assets | $465.79M | $999.71M |
| Total Current Liabilities | $52.06M | $158.63M |
| Long-Term Debt | $77.83M | $205.85M |
| Total Shareholders Equity | $389.16M | $1.21B |
| Retained Earnings | $-570.72M | $99.23M |
| Property, Plant & Equipment | $21.26M | $274.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PRCT | PEN |
|---|---|---|
| Operating Cash Flow | $-11.65M | $46.01M |
| Capital Expenditures | $-1.84M | $-13.47M |
| Free Cash Flow | $-18.82M | $35.50M |
| Debt Repayment | N/A | $-613,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PRCT | PEN |
|---|---|---|
| Shares Short | 6.82M | 1.83M |
| Short Ratio | 9.53 | 4.26 |
| Short % of Float | 0.15% | 0.07% |
| Average Daily Volume (10 Day) | 1,476,630 | 628,300 |
| Average Daily Volume (90 Day) | 1,040,502 | 480,977 |
| Shares Outstanding | 54.72M | 38.49M |
| Float Shares | 53.21M | 37.66M |
| % Held by Insiders | 0.04% | 0.04% |
| % Held by Institutions | 0.94% | 0.91% |
Dividend Analysis & Yield Comparison: Procept BioRobotics vs Penumbra
| Metric | PRCT | PEN |
|---|---|---|
| Last 12-Month Dividend | $0.38 | N/A |
| Last 12-Month Dividend Yield | 0.64% | N/A |
| 3-Year Avg Annual Dividend | $0.53 | N/A |
| 3-Year Avg Dividend Yield | 0.12% | N/A |
| 3-Year Total Dividends | $1.59 | N/A |
| Ex-Dividend Date | Mar 31, 2025 | N/A |